ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REVBU Revelation Biosciences Inc

0.2897
0.00 (0.00%)
Pre Market
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.24
Ask Price 0.3039
News -
Share Name Share Symbol Market Stock Type
Revelation Biosciences Inc REVBU NASDAQ Trust
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.2897 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.2897
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0  0.2897 USD

Revelation Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 2.17M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Revelation Biosciences

Real-Time news about Revelation Biosciences Inc (NASDAQ): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No REVBU Message Board. Create One! See More Posts on REVBU Message Board See More Message Board Posts

REVBU Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Your Recent History

Delayed Upgrade Clock